Arcturus Therapeutics Ltd (OQ:ARCT)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for ARCT within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET June 1st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
May 22/20 May 20/20 Ultragenyx Pharmaceutical Inc. Direct Ownership Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -600,000  
May 22/20 May 20/20 Ultragenyx Pharmaceutical Inc. Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 600,000 $16.00
Feb 20/20 Feb 18/20 Chivukula Pad Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 60,000  
Feb 20/20 Feb 18/20 Kummerfeld Keith C Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 10,000  
Feb 20/20 Feb 18/20 Hughes Steven George Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 75,000  
Feb 20/20 Feb 18/20 Sassine Andy Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 80,000  
Feb 20/20 Feb 18/20 Payne Joseph E Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 100,000  
Dec 9/19 Dec 5/19 Sassine Andy Direct Ownership Common Stock P - Open market or private purchase 5,649 $9.73
Dec 5/19 Dec 3/19 Sassine Andy Direct Ownership Common Stock P - Open market or private purchase 10,000 $10.00
Oct 29/19 Oct 25/19 Barlow James F Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 15,000  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for ARCT within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET June 1st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
May 22/20 May 20/20 Ultragenyx Pharmaceutical Inc. Direct Ownership Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -600,000  
May 22/20 May 20/20 Ultragenyx Pharmaceutical Inc. Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 600,000 $16.00
Feb 20/20 Feb 18/20 Chivukula Pad Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 60,000  
Feb 20/20 Feb 18/20 Kummerfeld Keith C Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 10,000  
Feb 20/20 Feb 18/20 Hughes Steven George Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 75,000  
Feb 20/20 Feb 18/20 Sassine Andy Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 80,000  
Feb 20/20 Feb 18/20 Payne Joseph E Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 100,000  
Dec 9/19 Dec 5/19 Sassine Andy Direct Ownership Common Stock P - Open market or private purchase 5,649 $9.73
Dec 5/19 Dec 3/19 Sassine Andy Direct Ownership Common Stock P - Open market or private purchase 10,000 $10.00
Oct 29/19 Oct 25/19 Barlow James F Direct Ownership Stock Option (right to buy) A - Grant, award or other under Rule 16b-3(d) 15,000  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $ARCT

Competitors

Competitors with Recent Insider Filings
No competitors with recent insider filings.